Keywords: lilly, generex, end, diabetes, deal, biotechnology, eli
Lilly and Generex end diabetes deal
Article | 02 June 2003
Generex Biotechnology and Eli Lilly have decided to terminate their development and licensing agreement for buccal formulations of insulin. The ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
